BHE inhibits the cyclin B1/cDC2 signaling pathways to achieve antitumor effects, which demonstrates its great potential as a new anticancer drug for the treatment of patients with HCC and provides a theoretical basis for the further development and utilization of blue honeysuckle in tumor therapy. This evidence concerns the gene CCNB1 and neoplasm.